Press coverage about Catalent (NYSE:CTLT) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalent earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.8356359678421 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Catalent (NYSE CTLT) opened at $42.94 on Friday. The stock has a market cap of $5,700.00, a price-to-earnings ratio of 49.93, a PEG ratio of 2.69 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. Catalent has a 1-year low of $25.72 and a 1-year high of $43.42.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 earnings per share. research analysts predict that Catalent will post 1.47 EPS for the current fiscal year.

Several research analysts have commented on CTLT shares. ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, October 5th. Needham & Company LLC restated a “hold” rating on shares of Catalent in a research report on Monday, October 23rd. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $49.00 price objective for the company in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies boosted their price objective on shares of Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, November 7th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $44.44.

In related news, insider John R. Chiminski sold 181,458 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Uwe Roehrhoff acquired 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was bought at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Catalent (CTLT) Receives Media Sentiment Score of 0.11” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.